Skip to main content
. Author manuscript; available in PMC: 2017 Aug 11.
Published in final edited form as: Int J Drug Policy. 2013 Sep 9;24(6):e91–e98. doi: 10.1016/j.drugpo.2013.09.001

Table 1.

Characteristics of study participants (N =110).

Characteristic Total sample (N =110) MMT(N=57) No MMT(N=53) p-value
Site
 Mykolayiv 20 (18.2%) 16 (28.1%) 4 (7.5%) <0.001
 Odessa 25 (22.7%) 22 (38.6%) 3 (5.7%)
 Kherson 20 (18.2%) 19 (33.3%) 1 (1.9%)
 Kyiv 12 (10.9%) 0 (0%) 12 (22.6%)
 Donetsk 13 (11.8%) 0 (0%) 13 (24.5%)
 Dnipropetrovsk 20 (18.2%) 0 (0%) 20 (37.7%)
Age (median = 36.0 years)
 ≤36 years old 56 (50.9%) 22 (38.6%) 34 (64.2%) 0.007
 >36 years old 54 (49.1%) 35 (61.4%) 19 (35.8%)
Gender
 Female 21 (19.1%) 10 (17.5%) 11 (20.8%) 0.669
 Male 89 (80.9%) 47 (82.5%) 42 (79.2%)
Educationa
 5–9 years 30 (27.3%) 12 (21.1%) 18 (34.0%) 0.311
 10–12 years 38 (34.5%) 21 (36.8%) 17 (32.1%)
 Higher education or professional technical 42 (38.2%) 24 (42.1%) 18 (34.0%)
Marriedb
 Yes 27 (24.5%) 14 (24.6%) 13 (24.5%) 0.997
 No 83 (75.5%) 43 (75.4%) 40 (75.5%)
Employed when hospitalized
 Yes 24 (21.8%) 13 (22.8%) 11 (20.8%) 0.838
 No 86 (78.2%) 44 (77.2%) 42 (79.2%)
Income
 None 35 (31.8%) 19 (33.3%) 16 (30.2%) 0.723
 Any 75 (68.2%) 38 (66.7%) 37 (69.8%)
Living arrangements when hospitalized
 Alone 17 (15.5%) 8 (14.0%) 9 (17.0%) 0.747
 With partner 31 (28.2%) 15 (26.3%) 16 (30.2%)
 With relatives/friends 58 (52.7%) 31 (54.4%) 27 (50.9%)
 Homeless/lives in hospital 4 (3.6%) 3 (5.3%) 1 (1.9%)
Lifetime duration of drug use (median = 17.0 years)
 ≤ 17 years 56 (50.9%) 20 (35.1%) 36 (67.9%) 0.001
 >17 years 54 (49.1%) 37 (64.9%) 17 (32.1%)
Any lifetime amphetamines use
 Yes 45 (40.9%) 20 (35.1%) 25 (47.2%) 0.198
 No 65 (59.1%) 37 (64.9%) 28 (52.8%)
Amphetamines use 30 days prior to hospitalization
 Yes 16 (14.5%) 3 (5.3%) 13 (24.5%) 0.004
 No 94 (85.5%) 54 (94.7%) 40 (75.5%)
HIV status
 Positive 75 (68.2%) 39 (68.4%) 36 (67.9%) 0.679
 Negative 15 (13.6%) 9 (15.8%) 6 (11.3%)
 Status unknown 20 (18.2%) 9 (15.8%) 11 (20.8%)
Ever received antiretroviral therapy (N=75)
 Yes 50 (66.7%) 23 (59.0%) 27 (75.0%) 0.141
 No 25 (33.3%) 16 (41.0%) 9 (25.0%)
History of incarcerations
 Yes 94 (85.5%) 50 (87.7%) 44 (83.0%) 0.485
 No 16 (14.5%) 7 (12.3%) 9 (17.0%)
Mean number of incarcerations (±SD), among those, who have ever been incarcerated
 (N = 94, Range: 1–12) 2.87 ± 2.01 2.98 ± 2.18 2.75 ±1.82 0.583
Tuberculosis treatment status
 New diagnosis 21 (19.1%) 10 (17.5%) 11 (20.8%) 0.669
 Previously treated 89 (80.9%) 47 (82.5%) 42 (79.2%)
Prescribed TB treatment
 First line (or unknown) 69 (62.7%) 38 (66.7%) 31 (58.5%) 0.376
 At least one second line medication 41 (37.3%) 19 (33.3%) 22 (41.5%)
Number of TB medications prescribed at baseline (median = 4 drugs, N = 108)
 <4 drugs (2–3 drugs) 31 (28.7%) 22 (38.6%) 9 (17.6%) 0.016
 ≥4 drugs (4–6 drugs) 77 (71.3%) 35 (61.4%) 42 (82.4%)
Mean number of TB medications prescribed at baseline (± SD), (Range: 2–6)
4.07 ± 1.13 3.82 ±1.17 4.35 ± 1.04 0.015
Duration of inpatient stay at the baseline date (median = 75.0 days)
 ≤75 days 55 (50.0%) 16 (28.1%) 39 (73.6%) <0.001
 >75 days 55 (50.0%) 41 (71.9%) 14 (26.4%)
Mean duration of inpatient stay at the baseline date
 (days, ±SD), (Range: 0–706) 125.1 ±145.9 173.1 ±170.4 73.5 ±90.2 <0.001
Mean methadone dose
 (mg, ±SD), (Range: 12–225) 81.2 ±40.0

Results are significant at the 0.05 level.

a

Indicated highest level of education attained.

b

Registered, unregistered marriage and having a partner; Unmarried, single, separated or widowed, including unknown status.